MEDICAL RADIATION THERAPIES
Ontology highlight
ABSTRACT: We assessed the clinical features and treatment outcome in immunocompetent patients of primary central nervous system lymphoma (PCNSL) by retrospective chart review from 2005–12. Overall survival was analyzed by Kaplan-Meier method. 17 patients met the study criterion (male: female = 11:6). Median age at presentation was 47 years (range 15–74 years). Presenting features included motor impairment in 8(47.06%), raised intracranial tension in 6(35.29%) and seizures in 3(17.65%) patients. Contrast enhanced MRI of brain revealed periventricular lesion, with homogenous contrast enhancement and perilesional edema. Lesions were unifocal in 8(47.06%) and multifocal in 9(52.94%) patients. Stereotactic biopsy and decompression of tumor were performed in 2(11.76%) and 7(41.18%) patients respectively whereas the remaining 8(47.06%) patients were treated on basis of radiology. Histopathology showed diffuse large B cell lymphoma (CD20 + ve) in all 9 patients. Systemic lymphoma workup was negative in all patients. Systemic chemotherapy (median 6 cycles) was given in 14(82.35%) patients. The most common regimen incorporated high dose methotrexate (3gm/m2 IV D1 q3wk) with leucovorin rescue in 12(70.59%) patients- single agent in 10 and in combination in 2 patients. Whole brain radiation (WBRT-median dose 45Gy/25fractions/5weeks) was given in 12(70.59%) patients. After a median follow-up of 21 months (mean 26.24 months), 9(52.94%) patients are in complete response, 2(11.76%) patients are alive with evidence of disease and 6(35.29%) patients expired due to disease progression. The median overall survival was noted to be 34 months (actuarial rate of overall survival at 2 and 3 years- 63.3% and 43.4% respectively). On univariate analysis (Log rank test), KPS (<70 versus ?70) was a significant predictor of overall survival (p = 0.01) whereas age, sex, extent of surgery, treatment modality and choice of chemotherapy had no significant impact upon survival. Stereotactic biopsy followed by high dose single agent methotrexate with WBRT is a reasonable treatment strategy for PCNSL in a developing nation.
SUBMITTER: Ahmed I
PROVIDER: S-EPMC3823894 | biostudies-literature | 2013 Nov
REPOSITORIES: biostudies-literature
ACCESS DATA